Active substanceCollagenaseCollagenase
Similar drugsTo uncover
  • Collalisin®
    lyophilizate locally 
    SPbNIIVS FMBA, FSUE     Russia
  • Dosage form: & nbsp

    lyophilizate for solution for local and parenteral use

    Composition:

    Active substances:

    Collagenase - 100, 200, 300, 400, 500, 600, 700, 800, 900 and 1000 KE (collagenase units).

    Description:

    Powder or porous mass of white color.

    Pharmacotherapeutic group:Proteolytic agent
    ATX: & nbsp

    D.03.B.A   Proteolytic enzymes

    D.03.B.A.03   Bromelaines

    Pharmacodynamics:

    Collalyzin® selectively acts on collagen (the main component of connective tissue), causing its destruction.

    The introduction of collagenin® in small doses in the tissues of the calcified arch of the eye, starting from 15 days after the burn, leads either to a delay in the formation of scar tissue between the burned surfaces (eyelid and eyeball) or to the prevention of the development of the narrow symphobaron.

    When exposed to aqueous solutions of Kollalizina® on keloid tissue, a lytic effect sets in, the degree of which depends on the exposure time.

    Indications:Kollalizin® is used as a means of prevention and treatment of simbelfaron, cicatricial changes in the skin of the eyelids (keloid scars), conjunctiva of the eyeball after a burn, with strictures of the lacrimal ducts (tear ducts and lacrimal canal),corneal opacities, plastic iridocyclitis (in the stage of abatement of inflammatory phenomena), secondary cataracts, vitreosis, scarring of the retina, traumatic haemorrhage into the vitreous, occupying more than 1/2 of its volume and within 3 days after the formation of the hemophthalmus.
    Contraindications:

    The use of Kollalizina® is contraindicated in the unfinished corneal epithelization process after a burn, the combination of simbelfarone with a corneal ulcer, the presence of defects in the sclera, and vitreous hemorrhage 1/2 its volume, the presence of signs of blood coagulation in the vitreous body, a pronounced reaction after the administration of 1 KE, during pregnancy, lactation, childhood to 18 years.

    Dosing and Administration:

    Immediately before the application of Callalizine®, the contents of the ampoule are dissolved in 0.5 % solution of novocain, 0.9 % solution of sodium chloride for injection or in water for injection.

    The drug is administered subconjunctivally, directly into the lesion (spike, scar, vitreous, etc.) by electrophoresis, phonophoresis, and also applied dermally.

    Before applying Kollalizina®, the sensitivity of the patient to the drug is checked,for which under the conjunctiva of the diseased eye, 1 KE is administered and 48 hours are observed. In the absence of an allergic reaction, treatment is performed. When the product is applied spontaneously, the skin is tolerated by skin, for which skin tests are performed with the application of a solution of Collalisin® in therapeutic doses for 24 and 48 hours.

    1. For the prevention of post-burn symphylarphone Collalisin® is administered at 10 KE in 0.5 % solution of novocaine in the calcified arch after complete corneal epithelialization. Re-introduction is carried out after 2-3 days (after the reactivation of the previous injection subsided). The course of treatment is 2-3 weeks, the total dose of 60-70 KE, the number of injections - 5-7.

    2. For the treatment of Simblefaron, keloid and other scars of the eyelids, Callalizin® is injected into the adhesion between the eyelid and the eyeball (immediately under the conjunctiva) or into the rumen at doses that cause limited necrosis - 100 KE in 0.5% solution of novocaine. The procedure is performed under close eye control using a binocular microscope. Repeated injection is performed 2-5 days after the reactivation subsides. To lick the adhesions between the eyelid and the eyeball, 3 injections are sufficient. The total dose is 300 KE, the duration of treatment is 3 weeks.

    3. Treatment of narrowing of the tear ducts (tear ducts, tear duct) is performed by washing with Kollalizin® solution (daily or every other day) 50 KE in 2 ml of 0.5% solution of novocaine. The course of treatment is 7-10 procedures, the repeated course of treatment is possible in 2-3 weeks.

    4. Treatment of corneal opacities, plastic iridocyclitis (posterior synechiae) and secondary cataracts are performed in one of the following ways:

    a) Electrophoresis. Collalyzin® from the solution (50 KE with 10 ml of water for injection) is injected into the eye from the positive pole, the electric current is up to 1 mA, the duration of the procedure is up to 10 minutes. The course of treatment - 10 procedures, re-holding the course is possible in 2-3 weeks,

    b) Phonophoresis. Collagenin® in a dose of 50 KE (in 10 ml of water for injection) is injected into the eye with the help of the "�?УТ 0,88 - 4 - 2" sensor of the "Ultrasonic T-5" device. The intensity is 0.2 W / cm, the duration of the procedure is 5 minutes. The course consists of 10 procedures, can be repeated after 2-3 weeks.

    at) Electro-phonophoresis (a combination of two techniques). On the background of phonophoresis electrophoresis is connected. The duration of the procedures is as in points "a" and "b". A course of treatment can be repeated after 2-3 weeks.

    d) Subconjunctival administration.Collagenin® daily or every other day is administered under the conjunctiva of the eyeball at a dose of 10 ICE in 0.2 ml of 0.5 % solution of novocaine. The course of treatment is 7-10 injections, the total dose of 70-100 KE. The second course is carried out after 2-3 weeks.

    5. Treatment of opacities of the vitreous, organized hemophthalmia and cicatrical process in the retina is carried out by subconjunctival (see paragraph "4 g" above) or retrobulbar injections of Collalisin ® 'Retrobulbaric injections (under the tenon capsule) are produced every other day at a dose of 10 KE in 0.2 ml of 0 , 5% solution of novocaine. The course of treatment includes 7-10 injections, the total dose of 70-100 KE. Repeated courses can be conducted after 2-3 weeks.

    6. For the treatment of traumatic hemorrhage in the vitreous Collysin® is administered once for 1 KE in 0.2 ml of 0.9 % solution of sodium chloride in the central zone of the vitreous body through the incision of the sclera in the region of the flat part of the ciliary body.

    7. Nasal application of Collalisin ® is recommended for the prevention of rumen hypertrophy in patients after dermatology, used for the removal of scarring, facial wrinkles, for the prevention of scar formation after electrocoagulation of various skin lesions.Treatment begins in the postoperative period after complete healing of the wound or epithelization of the wound surface. Collalyzin® is applied to the scar every day at a dose of 500 KE c. 10 ml of water for injection. The course of treatment is 4-5 weeks, the total dose is 15,000-30000 KE.

    For the prevention of scar formation in patients after excision of keloids with an increased tendency to excessive connective tissue proliferation (treatment start in the postoperative period after full healing of wounds or epithelization of the wound surface), and for treatment of hypertrophic scars and fresh growing keloids, for formed scarring prescription is not more than a year, the drug is recommended to use the method of electrophoresis. The aqueous solutions of Collalisin® are injected from the positive electrode for 20 minutes at a current of 0.03-0.1 mA per cm2. The course of treatment does not exceed 15 procedures every other day. A total of 2-3 courses of treatment at intervals of 2 months. The dose of Collalisin® for electrophoresis is selected taking into account the size, stage of development of the scar and its clinical manifestations. For the treatment of hypertrophic scars Kollalizin® appoint 500-1000 KE dissolved in 10 ml of water for injections a total dose 22500-45000 KE.For fresh growing cicatricial scars, with formed cicatrixes older than a year, and also after excision of keloid scars in individuals with an increased tendency to excessive proliferation of connective tissue, the drug is prescribed for 1000-2000 KE in 10 ml of water for injection at a total dose of 45,000- 900,000 KE ( on 3 courses of treatment).

    Side effects:

    When using Callalizin®, corneal ulcers and an allergic reaction are possible. To prevent these phenomena, treatment should be started only after the epithelialization of the cornea has ended and a negative sample is obtained for sensitivity to Collalisin®.

    When a corneal ulcer occurs, the drug is immediately withdrawn and antibacterial drugs and agents that stimulate epithelization are prescribed.

    With allergic reactions, the drug is discontinued and administered antiallergic treatment.

    Overdose:

    Data on drug overdose are absent.

    Form release / dosage:

    Liofilizate for cooking solution for local and parenteral use in ampoules of 100, 200, 300, 400, 500, 600, 700, 800, 900 and 1000 KE.

    Packaging:

    For 10 ampoules in a box or a pack of cardboard with instructions for use and a scarifier ampoule.

    For 1, 3 or 5 ampoules in a contour acheive box in a box or a pack of cardboard with instructions for use and a scapegrator ampoule.

    When packing ampoules with notches, rings and fracture points, ampoule scalers do not invest.

    Storage conditions:In a dry, the dark place at a temperature of 4 ° C to 8 ° C. Keep out of the reach of children.
    Shelf life:

    2 years. Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-005615/09
    Date of registration:13.07.2009 / 07.05.2014
    Expiration Date:Unlimited
    The owner of the registration certificate:SPbNIIVS FMBA, FSUE SPbNIIVS FMBA, FSUE Russia
    Manufacturer: & nbsp
    Information update date: & nbsp31.01.2018
    Illustrated instructions
      Instructions
      Up